» GU Cancer

GU Cancer


ARMOR2: A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer (NCT01709734)
The purpose of this clinical trial is to evaluate the safety and efficacy of galeterone in castration resistant prostate cancer (CRPC) patients.
Website: http://www.clinicaltrials.gov/ct2/show/NCT01709734?term=armor2&rank=1
Principal Investigator: Dr. Jason Taksey
Research Staff:  Emily Ross, CCRC – (443)481-4392
                                     Venita Alston Crawford, RN – (443)481-4393

Adjuvant Axitinib Treatment of Renal Cancer: A Randomized Double-Blind Phase 3 Study of Adjuvant Axitinib vs. Placebo in Subjects at High Risk of Recurrent Renal Cell Cancer�
The purpose of this trial is to determine if supplementing therapy with Axitinib will prevent or delay the recurrence of renal cell cancer after surgery to remove the primary tumor in high risk patients �
Website: http://clinicaltrials.gov/ct2/show/NCT01599754?term=ADJUVANT+AXITINIB+TREATMENT+OF+RENAL+CANCER%3A+A+RANDOMIZED&rank=1
Principal Investigator: Jason Taksey, MD.
Research Staff:  Venita Crawford, RN: (443) 481-4393
                                 Steven P. DeMartino, CCRC, CRT, RPFT, AEC: (443) 481-4390

R0534: SPPORT: A Phase III Trial of Short term Androgen Deprivation with Pelvic Lymph Node or Prostate bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy
The purpose of this clinical trial is to study prostate radiation therapy. A steroid hormone called Androgen can cause the grown of prostate cancer cells. The purpose of this study is to determine how well prostate radiation therapy alone works compared to short –term androgen deprivation therapy given together with pelvic lymph node radiation therapy, either with or without prostate radiation therapy. This study is used in treating patients with a rising PSA after surgery for prostate cancer.
Website: link
Principal Investigator: Dr. Angel Torano – (443)481-5800
Research Coordinator: Elizabeth Egan, R.N. – (443)481-5811

R0815: A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer
The purpose of this study is to compare radiation therapy to androgen-deprivation therapy. Androgen-deprivation therapy may lessen the amount of androgens made by the body, which can cause the growth of prostate cancer cells. It is unknown how affective radiation therapy alone is compared with radiation therapy given together with androgen-deprivation therapy in treating patients with prostate cancer.
Website: http://clinicaltrials.gov/ct2/show/NCT00936390?term=A+Phase+III+Prospective+Randomized+Trial+of+Dose-Escalated+Radiotherapy&rank=1
Principal Investigator:
Dr. Angel Torano – (443)481-5800
Research Coordinator: Elizabeth Egan, R.N. – (443)481-5811

Our Studies